Jim Cramer on Johnson & Johnson: “One of the Best Pharmas There Is”

Group 1 - Johnson & Johnson reported a healthy revenue beat and a modest earnings beat, with a strong full-year forecast, but the stock remained unchanged after the earnings report [1] - The stock experienced a significant decline intraday, influenced by a previous increase of over 40% last year and an additional 5% year-to-date prior to the earnings announcement [1] - The company has spun off its orthopedics division, allowing it to focus on its pharmaceutical business, which is expected to perform better without the commoditized orthopedics segment [2] Group 2 - Johnson & Johnson's pharmaceutical pipeline includes some of the best drugs, which are expected to shine without the constraints of the orthopedics business [2] - The company faces ongoing lawsuits related to its talc products, but these legal challenges are perceived to have less impact on the stock's performance as the company is actively fighting each claim [2] - There is a belief that certain AI stocks may offer greater upside potential compared to Johnson & Johnson, indicating a competitive investment landscape [3]